Vanguard Capital Management
ASBP

Vanguard Capital Management’s Aspire Biopharma ASBP Stock Holding History

Vanguard Capital Management’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.6K Buy
10,408
+10,146
+3,873% +$103K ﹤0.01% 3928
2026
Q1 		$8.1K Buy
+262
New +$14K ﹤0.01% 4025

Other funds holding ASBP

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.73B AUM 42.12% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $567M AUM 0.34% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Vanguard Capital Management's ASBP Position: Q2 2026 in Review

Vanguard Capital Management increased its Aspire Biopharma (ASBP) stake by 3,873% in Q2 2026, buying an estimated $103K and bringing the position to 10,408 shares worth $55.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3928.

Vanguard Capital Management first reported a position in ASBP in Q1 2026 and has held it in 2 quarters since. 14 funds tracked by Wall St. Rank hold ASBP as of Q2 2026.

  • Vanguard Capital Management held 10,408 shares of Aspire Biopharma worth $55.6K as of Q2 2026.
  • Vanguard Capital Management bought 10,146 Aspire Biopharma shares in Q2 2026, an estimated $103K.
  • Aspire Biopharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3928 holding.
  • Vanguard Capital Management first reported a position in Aspire Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 14 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.